|
|
| Line 2,213: |
Line 2,213: |
| | | | | |
| | || | | | || |
| |
| |
| |
| |
| |}<br />
| |
|
| |
| ==WHO Classification of Tumours of the Central Nervous System Content==
| |
| {| class="wikitable"
| |
| |-
| |
| !'''Disease'''!!'''Page Type'''!!'''Author'''
| |
| !'''Date Assigned to Author'''
| |
| !'''Target Completion Date'''
| |
| !'''Author Content (Pending or Complete)'''
| |
| !'''Date Completed by Author'''!!'''Associate Editor'''
| |
| !'''Date of Last Editor Review'''
| |
| !'''Notes'''
| |
| |-
| |
| |Medulloblastoma, WNT-activated||Disease||Lisa Lansdon, PhD (LGG trainee just finished), Midhat Farooqi, MD (mentor), Children's Mercy Hospital Kansas City
| |
| |9/20/21
| |
| |
| |
| |COMPLETE
| |
| |
| |
| |Holli Drendel (interim)/Laveniya Satgunaseelan (LS)
| |
| |9/22/2022
| |
| |2021 template added
| |
| |-
| |
| |Paediatric-Type Diffuse High-Grade Gliomas
| |
| |Overview
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |2021 template added
| |
| |-
| |
| |Diffuse Midline Glioma, H3 K27-Altered
| |
| |Disease
| |
| |Laveniya Satgunaseelan (Linda Cooley - previous version)
| |
| |
| |
| |
| |
| |PENDING
| |
| |
| |
| |Laveniya Satgunaseelan (LS)
| |
| |
| |
| |2021 template added
| |
| |-
| |
| |Diffuse Hemispheric Glioma, H3 G34-Mutant
| |
| |Disease
| |
| |Xiaolin (Lynn) Hu
| |
| |2/21/2022
| |
| |
| |
| |PENDING
| |
| |
| |
| |LS
| |
| |
| |
| |2021 template added
| |
| |-
| |
| |Diffuse Paediatric-Type High-Grade Glioma, H3-Wildtype and IDH-Wildtype
| |
| |Disease
| |
| |Madina Sukhanova
| |
| |10/28/2022
| |
| |
| |
| |PENDING
| |
| |
| |
| |LS
| |
| |
| |
| |2021 template added
| |
| |-
| |
| |Infant-Type Hemispheric Glioma
| |
| |Disease
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |2021 template added
| |
| |-
| |
| |Astrocytoma, IDH-Mutant
| |
| |Disease
| |
| |Riley Lochner (trainee), Shashi Shetty (mentor)
| |
| |3/3/2022
| |
| |
| |
| |PENDING
| |
| |
| |
| |LS
| |
| |
| |
| |2021 template added
| |
| |-
| |
| |Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted
| |
| |Disease
| |
| |Riley Lochner (trainee), Shashi Shetty (mentor)
| |
| |3/3/2022
| |
| |
| |
| |PENDING
| |
| |
| |
| |LS
| |
| |
| |
| |2021 template added
| |
| |-
| |
| |Ganglioglioma
| |
| |Disease
| |
| |Leila Moayed-Aloei
| |
| |6/30/2022
| |
| |
| |
| |COMPLETE
| |
| |
| |
| |LS
| |
| |
| |
| |2021 template added
| |
| |-
| |
| |Pilocytic Astrocytoma
| |
| |Disease
| |
| |Jeremy Pulvers
| |
| |9/13/2022
| |
| |
| |
| |PENDING
| |
| |
| |
| |LS
| |
| |
| |
| |2021 template added
| |
| |-
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |-
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| | | | | |
| | | | | |
| Line 2,533: |
Line 2,236: |
| | | | | |
| | | | | |
| |-
| |
| |}<br />
| |
|
| |
| ==WHO Classification of Tumours of Breast Tumours (5th Edition) Content==
| |
| {| class="wikitable"
| |
| |-
| |
| !'''Disease'''!!'''Page Type'''!!'''Author'''
| |
| !'''Date Assigned to Author'''
| |
| !'''Target Completion Date'''
| |
| !'''Author Content (Pending or Complete)'''
| |
| !'''Date Completed by Author'''!!'''Associate Editor'''
| |
| !'''Date of Last Editor Review'''
| |
| !'''Notes'''
| |
| |-
| |
| |Adenoid Cystic Carcinoma
| |
| |Disease||Katherine Geiersbach
| |
| |10/12/02022
| |
| |
| |
| |PENDING
| |
| |
| |
| |Hui Chen
| |
| |
| |
| |2021 template added
| |
| |-
| |
| |Secretory Carcinoma
| |
| |Disease
| |
| |Hui Chen
| |
| |10/12/2022
| |
| |
| |
| |PENDING
| |
| |
| |
| |Katherine Geiersbach
| |
| |
| |
| |2021 template added
| |
| |- | | |- |
| |}<br /> | | |}<br /> |
| Line 3,672: |
Line 3,341: |
| | | | | |
| |- | | |- |
| |} | | |}<br /> |
| | ==WHO Classification of Tumours of Breast Tumours (5th Edition) Content== |
| | {| class="wikitable" |
| | |- |
| | !'''Disease'''!!'''Page Type'''!!'''Author''' |
| | !'''Date Assigned to Author''' |
| | !'''Target Completion Date''' |
| | !'''Author Content (Pending or Complete)''' |
| | !'''Date Completed by Author'''!!'''Associate Editor''' |
| | !'''Date of Last Editor Review''' |
| | !'''Notes''' |
| | |- |
| | |Adenoid Cystic Carcinoma |
| | |Disease||Katherine Geiersbach |
| | |10/12/02022 |
| | | |
| | |PENDING |
| | | |
| | |Hui Chen |
| | | |
| | |2021 template added |
| | |- |
| | |Secretory Carcinoma |
| | |Disease |
| | |Hui Chen |
| | |10/12/2022 |
| | | |
| | |PENDING |
| | | |
| | |Katherine Geiersbach |
| | | |
| | |2021 template added |
| | |- |
| | |}<br /> |
|
| |
|
| ==WHO Breast tumours (5th ed.) Content== | | ==WHO Breast tumours (5th ed.) Content== |